On May 9, 2018, Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” ) closed an underwritten public offering of units of the Company at a price of $1.05 per Unit for gross aggregate proceeds to the Company of $10,006,500 pursuant to an underwriting agreement dated April 24, 2018 with Mackie Research Capital Corporation (the “Underwriter”), as sole bookrunner and underwriter. The Underwriter also fully exercised the over-allotment option for additional aggregate gross proceeds to the Company of $1,500,975.
Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population.
Mackie Research Capital is one of Canada's largest independent full service investment firms.
Fasken advised Mackie Research Capital with a team that included Rubin Rapuch, Jessica Catton Rinaldi, Virginia Schweitzer, David Steinhauer, Armand Benitah, Mark Vanderveken and Roxana Monemdjou.
Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population.
Mackie Research Capital is one of Canada's largest independent full service investment firms.
Fasken advised Mackie Research Capital with a team that included Rubin Rapuch, Jessica Catton Rinaldi, Virginia Schweitzer, David Steinhauer, Armand Benitah, Mark Vanderveken and Roxana Monemdjou.
